EP3472316A4 - ANTI-C5 ANTIBODIES AND METHODS OF USE THEREOF - Google Patents

ANTI-C5 ANTIBODIES AND METHODS OF USE THEREOF Download PDF

Info

Publication number: EP3472316A4
Authority: EP; European Patent Office
Prior art keywords: antibodies; methods
Prior art date: 2016-06-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP17813418.5A

Other languages

German (de)

French (fr)

Other versions

EP3472316A1 (en

Inventor

Yoshinao Ruike

Zenjiro Sampei

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Chugai Pharmaceutical Co Ltd

Original Assignee

Chugai Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-06-17

Filing date

2017-06-16

Publication date

2020-01-08

2017-06-16 Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd

2019-04-24 Publication of EP3472316A1 publication Critical patent/EP3472316A1/en

2020-01-08 Publication of EP3472316A4 publication Critical patent/EP3472316A4/en

Status Pending legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

EP17813418.5A 2016-06-17 2017-06-16 ANTI-C5 ANTIBODIES AND METHODS OF USE THEREOF Pending EP3472316A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2016120325		2016-06-17
PCT/JP2017/022253 WO2017217524A1 (en)	2016-06-17	2017-06-16	Anti-c5 antibodies and methods of use

Publications (2)

Publication Number	Publication Date
EP3472316A1 EP3472316A1 (en)	2019-04-24
EP3472316A4 true EP3472316A4 (en)	2020-01-08

Family

ID=59969459

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP17813418.5A Pending EP3472316A4 (en)	2016-06-17	2017-06-16	ANTI-C5 ANTIBODIES AND METHODS OF USE THEREOF

Country Status (19)

Country	Link
EP (1)	EP3472316A4 (en)
JP (4)	JP6202774B1 (en)
KR (2)	KR101852739B1 (en)
CN (3)	CN115960223A (en)
AU (1)	AU2017285763B2 (en)
BR (1)	BR112018075688A2 (en)
CA (1)	CA3021956A1 (en)
CL (1)	CL2018003573A1 (en)
CR (1)	CR20190013A (en)
EA (1)	EA201990018A1 (en)
IL (2)	IL300611A (en)
MX (2)	MX2018015030A (en)
MY (1)	MY187848A (en)
PE (2)	PE20190394A1 (en)
PH (1)	PH12018502354B1 (en)
SG (2)	SG11201705584VA (en)
TW (5)	TWI610941B (en)
UA (1)	UA126561C2 (en)
WO (1)	WO2017217524A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2006381T3 (en)	2006-03-31	2016-02-22	Chugai Pharmaceutical Co Ltd	PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
DK2202245T3 (en)	2007-09-26	2016-11-21	Chugai Pharmaceutical Co Ltd	A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
UA121453C2 (en)	2008-04-11	2020-06-10	Чугей Сейяку Кабусікі Кайся	METHOD OF PREPARATION OF PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY
KR102385507B1 (en)	2010-11-30	2022-04-12	추가이 세이야쿠 가부시키가이샤	Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
JP6227191B1 (en)	2014-12-19	2017-11-08	中外製薬株式会社	Anti-myostatin antibody, polypeptide comprising mutant Fc region, and method of use
US9765135B2 (en)	2014-12-19	2017-09-19	Chugai Seiyaku Kabushiki Kaisha	Anti-C5 antibodies
EP3394098A4 (en)	2015-12-25	2019-11-13	Chugai Seiyaku Kabushiki Kaisha	ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
US10633434B2 (en)	2016-06-14	2020-04-28	Regeneron Pharmaceuticals, Inc.	Anti-C5 antibodies
TWI610941B (en) *	2016-06-17	2018-01-11	Chugai Seiyaku Kabushiki Kaisha	Anti-C5 antibody and method of use
IL264626B (en)	2016-08-05	2022-07-01	Chugai Pharmaceutical Co Ltd	A preparation for the prevention or treatment of diseases related to il-8
WO2019070714A1 (en) *	2017-10-04	2019-04-11	Alexion Pharmaceuticals, Inc.	Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis
CN120571008A (en)	2017-12-13	2025-09-02	瑞泽恩制药公司	Anti-C5 antibody combinations and uses thereof
KR20210055742A (en)	2018-09-06	2021-05-17	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	Humanized anti-C5 antibodies and uses thereof
EP3958901A4 (en) *	2019-04-24	2023-07-19	The Trustees of the University of Pennsylvania	Bi-functional humanized anti-c5 antibodies and factor h fusion proteins and uses thereof
CN113563467A (en) *	2020-04-28	2021-10-29	上海普铭生物科技有限公司	Antibodies against human complement protein C5 and uses thereof
CN115803058A (en) *	2020-07-15	2023-03-14	博奥信生物技术（南京）有限公司	Antibodies that bind C5 and uses thereof
WO2022134047A1 (en) *	2020-12-25	2022-06-30	The Trustees Of The University Of Pennsylvania	Humanized anti-c5 antibodies and factor h fusion proteins and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2016098356A1 (en) *	2014-12-19	2016-06-23	Chugai Seiyaku Kabushiki Kaisha	Anti-c5 antibodies and methods of use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0230985Y2 (en)	1985-07-08	1990-08-21
US6074642A (en) *	1994-05-02	2000-06-13	Alexion Pharmaceuticals, Inc.	Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
DE60143859D1 (en)	2001-06-12	2011-02-24	Ericsson Telefon Ab L M	SYNCHRONIZATION IN A TERRESTRIAL UMTS RADIO ACCESS NETWORK (UTRAN)
BRPI0211953B8 (en)	2001-08-17	2021-05-25	Genentech Inc	monoclonal antibody or antigen-binding fragment that binds to c5 and c5a without the prevention of c5b formation, cell lineage, pharmaceutical composition, as well as in vitro method to inhibit c5a activity and in vitro diagnostic method
JP4333939B2 (en)	2001-08-27	2009-09-16	ロード・コーポレーション	Trolley wire suspension system
DE10253331A1 (en)	2002-11-14	2004-06-03	Symrise Gmbh & Co. Kg	Use of trans-pellitori as a flavoring
US7267849B2 (en)	2004-03-02	2007-09-11	Nitto Denko Corporation	Compensator for liquid crystal display
KR20080069889A (en)	2007-03-20	2008-07-29	(주)화도	Polyethylene tube
KR20100015773A (en) *	2007-03-22	2010-02-12	노파르티스 아게	C5 antigens and uses thereof
WO2008126921A1 (en)	2007-04-11	2008-10-23	Sekisui Chemical Co., Ltd.	Method for production of crosslinked polyvinyl acetal resin, and crosslinked polyvinyl acetal resin
UA121453C2 (en) *	2008-04-11	2020-06-10	Чугей Сейяку Кабусікі Кайся	METHOD OF PREPARATION OF PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY
ES2643411T3 (en) *	2008-08-05	2017-11-22	Novartis Ag	Compositions and methods for antibodies directed to the complement protein C5
KR20100054403A (en)	2008-11-14	2010-05-25	삼성전자주식회사	Online composition apparatus and method for writing by multiple participants
KR20150002894A (en) *	2010-03-11	2015-01-07	리나트 뉴로사이언스 코프.	ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
TW201206466A (en) *	2010-03-11	2012-02-16	Rinat Neuroscience Corp	Antibodies with pH dependent antigen binding
KR20110111007A (en)	2010-04-02	2011-10-10	이화여자대학교 산학협력단	Octahydro-binaphthol derivatives for L / D optical conversion and optical splitting
KR20110122011A (en)	2010-05-03	2011-11-09	황보철종	Store point integrated management system and method
EP2882778B1 (en) *	2012-08-13	2018-04-11	Regeneron Pharmaceuticals, Inc.	Anti-pcsk9 antibodies with ph-dependent binding characteristics
BR112015018438A2 (en) *	2013-01-31	2017-07-18	Seoul Nat Univ R&Db Foundation	c5 antibody and method for preventing and treating complement-related diseases
CA2897334A1 (en) *	2013-03-29	2014-10-02	Alexion Pharmaceuticals, Inc.	Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
NZ631007A (en) *	2014-03-07	2015-10-30	Alexion Pharma Inc	Anti-c5 antibodies having improved pharmacokinetics
SI3390442T1 (en) *	2015-12-18	2024-01-31	Chugai Seiyaku Kabushiki Kaisha	Anti-c5 antibodies and methods of use
TWI610941B (en) *	2016-06-17	2018-01-11	Chugai Seiyaku Kabushiki Kaisha	Anti-C5 antibody and method of use

2017
- 2017-06-16 TW TW106120143A patent/TWI610941B/en active
- 2017-06-16 TW TW112120479A patent/TW202337903A/en unknown
- 2017-06-16 KR KR1020177020545A patent/KR101852739B1/en active Active
- 2017-06-16 IL IL300611A patent/IL300611A/en unknown
- 2017-06-16 JP JP2017118226A patent/JP6202774B1/en active Active
- 2017-06-16 CN CN202211018018.5A patent/CN115960223A/en active Pending
- 2017-06-16 CR CR20190013A patent/CR20190013A/en unknown
- 2017-06-16 SG SG11201705584VA patent/SG11201705584VA/en unknown
- 2017-06-16 SG SG10201800265UA patent/SG10201800265UA/en unknown
- 2017-06-16 TW TW106141573A patent/TWI789369B/en active
- 2017-06-16 EA EA201990018A patent/EA201990018A1/en unknown
- 2017-06-16 MX MX2018015030A patent/MX2018015030A/en unknown
- 2017-06-16 IL IL263657A patent/IL263657B2/en unknown
- 2017-06-16 TW TW114113992A patent/TW202532438A/en unknown
- 2017-06-16 PE PE2018003148A patent/PE20190394A1/en unknown
- 2017-06-16 EP EP17813418.5A patent/EP3472316A4/en active Pending
- 2017-06-16 KR KR1020187010179A patent/KR102226975B1/en active Active
- 2017-06-16 PH PH1/2018/502354A patent/PH12018502354B1/en unknown
- 2017-06-16 CN CN201780036916.4A patent/CN109312326B/en active Active
- 2017-06-16 MY MYPI2018002581A patent/MY187848A/en unknown
- 2017-06-16 BR BR112018075688-1A patent/BR112018075688A2/en unknown
- 2017-06-16 CA CA3021956A patent/CA3021956A1/en active Pending
- 2017-06-16 PE PE2023002969A patent/PE20240825A1/en unknown
- 2017-06-16 CN CN202211023851.9A patent/CN115925922A/en active Pending
- 2017-06-16 TW TW111107923A patent/TWI807666B/en active
- 2017-06-16 WO PCT/JP2017/022253 patent/WO2017217524A1/en not_active Ceased
- 2017-06-16 AU AU2017285763A patent/AU2017285763B2/en active Active
- 2017-06-16 UA UAA201810992A patent/UA126561C2/en unknown
- 2017-08-28 JP JP2017162934A patent/JP7032077B2/en active Active
2018
- 2018-12-04 MX MX2023001360A patent/MX2023001360A/en unknown
- 2018-12-12 CL CL2018003573A patent/CL2018003573A1/en unknown
2022
- 2022-02-24 JP JP2022026406A patent/JP2022091748A/en active Pending
2024
- 2024-04-30 JP JP2024073302A patent/JP2024102181A/en active Pending

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2016098356A1 (en) *	2014-12-19	2016-06-23	Chugai Seiyaku Kabushiki Kaisha	Anti-c5 antibodies and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAKU FUKUZAWA ET AL: "Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases", SCIENTIFIC REPORTS, vol. 7, no. 1, 24 April 2017 (2017-04-24), XP055399003, DOI: 10.1038/s41598-017-01087-7 *

Also Published As

Publication number	Publication date
IL263657A (en)	2019-01-31
CN109312326B (en)	2022-09-09
MY187848A (en)	2021-10-26
UA126561C2 (en)	2022-11-02
SG10201800265UA (en)	2018-02-27
TWI807666B (en)	2023-07-01
PE20190394A1 (en)	2019-03-13
TW201809000A (en)	2018-03-16
CN115925922A (en)	2023-04-07
IL300611A (en)	2023-04-01
BR112018075688A2 (en)	2019-04-02
JP6202774B1 (en)	2017-09-27
CL2018003573A1 (en)	2019-02-01
RU2019100222A (en)	2020-07-17
AU2017285763B2 (en)	2024-02-01
IL263657B1 (en)	2025-08-01
KR20190009273A (en)	2019-01-28
NZ748003A (en)	2024-12-20
TW201808996A (en)	2018-03-16
JP2024102181A (en)	2024-07-30
IL263657B2 (en)	2025-12-01
PH12018502354A1 (en)	2019-09-23
PE20240825A1 (en)	2024-04-18
WO2017217524A1 (en)	2017-12-21
CR20190013A (en)	2019-03-05
JP2018009021A (en)	2018-01-18
TW202532438A (en)	2025-08-16
JP2017226655A (en)	2017-12-28
KR101852739B1 (en)	2018-04-30
EA201990018A1 (en)	2019-08-30
PH12018502354B1 (en)	2024-02-23
MX2018015030A (en)	2019-04-22
TW202239766A (en)	2022-10-16
TWI789369B (en)	2023-01-11
MX2023001360A (en)	2023-02-27
TWI610941B (en)	2018-01-11
CA3021956A1 (en)	2017-12-21
TW202337903A (en)	2023-10-01
SG11201705584VA (en)	2018-05-30
KR102226975B1 (en)	2021-03-11
RU2019100222A3 (en)	2020-11-05
JP2022091748A (en)	2022-06-21
JP7032077B2 (en)	2022-03-08
AU2017285763A1 (en)	2018-11-08
CN109312326A (en)	2019-02-05
CN115960223A (en)	2023-04-14
EP3472316A1 (en)	2019-04-24

Publication	Publication Date	Title
FR24C1044I2 (en)	2025-05-23	ANTI-C5 ANTIBODIES AND METHODS OF USE THEREOF
FR24C1050I1 (en)	2025-01-17	CHIMERIC ANTIGEN RECEPTORS BASED ON SINGLE-DOMAIN ANTIBODIES AND METHODS OF USE THEREOF
EP3472316A4 (en)	2020-01-08	ANTI-C5 ANTIBODIES AND METHODS OF USE THEREOF
EP3472200A4 (en)	2020-04-01	ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE THEREOF
EP3383914A4 (en)	2019-10-30	ANTI-OX40 ANTIBODIES AND METHODS OF USE
MA52753A (en)	2021-04-21	ANTI-SIRPA ANTIBODIES AND THEIR METHODS OF USE
MA53355A (en)	2022-03-16	ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF
EP3491025A4 (en)	2020-05-27	FCRN ANTIBODIES AND METHODS OF USE
EP3436476A4 (en)	2020-04-29	ANTI-RYK ANTIBODIES AND METHODS OF USE THEREOF
MA49950A (en)	2020-07-01	ANTI-B7-H4 ANTIBODIES AND PROCEDURES FOR USE
MA46529A (en)	2019-08-21	ANTI-LAG-3 ANTIBODIES AND PROCESSES FOR USE
MA45123A (en)	2019-04-10	ANTI-TIM-3 ANTIBODIES AND THEIR METHODS OF USE
MA50359A (en)	2020-08-19	ANTI-CD38 ANTIBODIES AND METHODS OF USE
MA50957A (en)	2020-10-14	ANTI-TIGIT ANTIBODIES AND THEIR METHODS OF USE
MA42043A (en)	2018-03-14	ANTI-OX40 ANTIBODIES AND METHODS OF USE THEREOF
EP3436048A4 (en)	2019-11-27	NEOANTIGENES AND METHODS OF USE
MA50956A (en)	2020-10-14	ANTI-CD137 ANTIBODIES AND RELATED METHODS OF USE
EP3383430A4 (en)	2019-12-18	ANTIBODIES AND THEIR METHODS OF USE
MA43018A (en)	2021-06-02	ANTI-PD1 ANTIBODIES AND METHODS OF USE
MA50949A (en)	2020-10-14	ANTI-CTLA-4 ANTIBODIES AND PROCESSES FOR USE
MA42446A (en)	2018-05-23	SPECIFIC ANTIBODIES OF HYPERPHOSPHORYLATED TAU PROTEIN AND THEIR USE METHODS
MA42971A (en)	2018-08-15	ANTI-PDL1 ANTIBODIES, ACTIVABLE ANTI-PLD1 ANTIBODIES, AND METHODS OF USE THEREOF
MA50948A (en)	2020-10-14	ANTIBODIES AND METHODS OF USING THE SAME
EP3731867A4 (en)	2022-04-06	ANTI-LRP5/6 ANTIBODIES AND METHODS OF USE THEREOF
MA47849A (en)	2020-01-29	ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE

Legal Events

Date	Code	Title	Description
2017-12-28	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2019-03-22	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2019-03-22	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2019-04-24	17P	Request for examination filed	Effective date: 20190117
2019-04-24	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2019-04-24	AX	Request for extension of the european patent	Extension state: BA ME
2019-09-25	DAV	Request for validation of the european patent (deleted)
2019-09-25	DAX	Request for extension of the european patent (deleted)
2020-01-08	A4	Supplementary search report drawn up and despatched	Effective date: 20191210
2020-01-08	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 16/18 20060101AFI20191204BHEP Ipc: A61P 7/00 20060101ALI20191204BHEP Ipc: C12N 15/09 20060101ALI20191204BHEP Ipc: A61K 39/395 20060101ALI20191204BHEP
2022-09-23	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2022-10-26	17Q	First examination report despatched	Effective date: 20220923